Ummunity Corp Now Planning for Fast Tracking


November 30, 2018 – TOWSON, MD /Company News – Ummunity Corp a biotech corporation. It is now preparing its protocol to fast track its Ummune-A-Care product that treats and prevents multiple disease families and strains of auto-immune disorders (including HIV/AIDS), digestive and diarrhea disorders from Colitis to Cholera, E Coli to Crohn’s and other major digestive disorders, pulmonary disorders including influenzas, and brain disorders such as dementia and Alzheimer as well as some cancers such as Leukemia and Hodgkin’s disease. There are many others.

Once protocols and other data is prepared, the company will apply for fast tracking. During fast tracking numerous pilot studies will be conducted due to the nature of the product for safety purposes for the families of above mentioned disorders, even though company pre-trials were conducted. Therefore, safety and efficacy are still under investigation and market authorization has not yet been obtained.

The fast tracking procedure will proceed with a rolling review which simply means the company can fill out sections of the New Drug Application (NDA) rather than wait for every section of the NDA to be completed. This requires early and frequent communication between the FDA and the company assuring that questions and issues are resolved quickly, often leading to earlier drug approval and access by patients.

Please see website for further explanations.

Any interested in volunteering as a participant in pilot studies is encouraged to contact us at Additionally if anyone qualifies for compassionate use please also contact